SCHEMBL859964

SCHEMBL859964

Oc1cccc(-n2cnnc2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 1/20 0.47
OPRD1 P41143 5/20 0.46
CA12 O43570 1/20 0.46
ALDH1A1 P00352 1/20 0.46
CA2 P00918 1/20 0.46
LMNA P02545 1/20 0.46
CYP3A4 P08684 1/20 0.46
CA5A P35218 1/20 0.46
CA9 Q16790 1/20 0.46
HSD17B10 Q99714 1/20 0.46
CA14 Q9ULX7 1/20 0.46
CA5B Q9Y2D0 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
OPRM1 P35372 4/20 0.45
GABRG2 P18507 1/20 0.44
GABRB3 P28472 1/20 0.44
GABRA5 P31644 1/20 0.44
GABRA3 P34903 1/20 0.44
NPC1 O15118 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30797813 1.00 FGFR1 (0.47) FGFR1OPRD1CA12ALDH1A1CA2
SCHEMBL27983626 0.84 GABRG2 (0.50) CA12LMNACYP3A4CA9MEN1
SCHEMBL406716 0.77 MAPT (0.56) FGFR1CA12ALDH1A1CA2LMNA
SCHEMBL29483362 0.76 IDO1 (0.64) LMNACYP3A4MEN1KMT2A
SCHEMBL3071130 0.76 IDO1 (0.64) LMNACYP3A4MEN1KMT2A
SCHEMBL2658313 0.74 MGLL (0.47) ALDH1A1MEN1KMT2AGABRG2GABRB3
SCHEMBL12841352 0.74 KEAP1 (0.52) ALDH1A1MEN1KMT2AGABRG2GABRB3
SCHEMBL30341093 0.74 MAPT (0.63) FGFR1CA12ALDH1A1CA2CYP3A4
SCHEMBL10053917 0.74 HSP90AA1 (0.47) ALDH1A1LMNACYP3A4GABRG2GABRB3
SCHEMBL30015400 0.74 MGLL (0.47) ALDH1A1MEN1KMT2AGABRG2GABRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111344284-B Compounds useful as inhibitors of isoprene cysteine carboxymethyltransferase 新加坡科技研究局 2024-03-12 CN disclosed
CN-111194215-B Methods and compositions for modulating splicing 斯基霍克疗法公司 2024-03-01 CN disclosed
CN-111499615-B Methods and compositions for modulating splicing 斯基霍克疗法公司 2024-02-02 CN disclosed
US-11834430-B2 Compounds useful as inhibitors of isoprenylcysteine carboxyl methyltransferase AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2023-12-05 US disclosed
US-11834430-B2 Compounds useful as inhibitors of isoprenylcysteine carboxyl methyltransferase AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2023-12-05 US disclosed
US-11834430-B2 Compounds useful as inhibitors of isoprenylcysteine carboxyl methyltransferase AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2023-12-05 US disclosed
US-20210130317-A1 Compounds Useful as Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2021-05-06 US disclosed
US-20210130317-A1 Compounds Useful as Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2021-05-06 US disclosed
CN-108842932-B High-adhesion polyolefin anti-adhesion film and preparation method thereof 江苏优珀斯材料科技有限公司 2021-03-19 CN disclosed
EP-3681878-A1 COMPOUNDS USEFUL AS INHIBITORS OF ISOPRENYLCYSTEINE CARBOXYL METHYLTRANSFERASE Agency for Science, Technology and Research (SG) 2020-07-22 EP disclosed
EP-3307715-A1 AROMATIC SULFONAMIDE DERIVATIVES Bayer Pharma Aktiengesellschaft (DE) 2018-04-18 EP disclosed
EP-2945950-B1 ISOMANNIDE DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE SANOFI SA (FR) 2017-03-01 EP disclosed
WO-2016198374-A1 AROMATIC SULFONAMIDE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-12-15 WO disclosed
CN-102459202-B As the inhibitor isoxazoline of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2015-11-25 CN disclosed
US-9149465-B2 Isoxazolines as inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2015-10-06 US disclosed
CN-102459202-A Isoxazolines as inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS INC 2012-05-16 CN disclosed
EP-2432771-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE Infinity Pharmaceuticals, Inc. (US) 2012-03-28 EP disclosed
WO-2011035064-A2 TRIAZOLE CATALYSTS AND METHODS OF MAKING AND USING THE SAME UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2011-03-24 WO disclosed
US-20110028478-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2011-02-03 US disclosed
WO-2010135360-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028478-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, HRH2 FGFR1 901/4885OPRD1 689/4885CA12 3102/4885
US-20210130317-A1 Compounds Useful as Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase ICMT, INMT, BHMT FGFR1 4109/4885OPRD1 4187/4885CA12 2896/4885
US-11834430-B2 Compounds useful as inhibitors of isoprenylcysteine carboxyl methyltransferase ICMT, INMT, BHMT FGFR1 4109/4885OPRD1 4187/4885CA12 2896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.